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Formulation of Treatment Recommendations
for Statins
To theEditorDrsRidkerandWilson1proposed that statinguide-
lines formulate treatment recommendations through consid-
erationof “… patientpopulations forwhomclinical trials have
demonstrated benefit.” They failed to provide a clear defini-
tion of benefit. The authors cited approximately 20 random-
ized clinical trials; however, the measures of benefit varied
widely between some of these trials.
In addition, the vascular events terminology is insuffi-
ciently specific. Efficacy measures in randomized clinical
trials of statins often include outcomes that differ in their
clinical importance, ranging from death to clinician-driven
end points such as revascularization procedures and hospi-
talizations.
For example, in the Scandinavian Simvastatin Survival
Study (4S),2 in which participants with a history of coronary
heart disease were enrolled, the primary efficacy measure
was total mortality. In the Subcutaneous Heparin and Angi-
oplasty Restenosis Prevention (SHARP) trial,3 in which par-
ticipants with chronic kidney disease were enrolled, the
modified efficacy outcome was a broad composite of events
(ie, nonfatal myocardial infarction, coronary death, non-
hemorrhagic stroke, or any arterial revascularization proce-
dure). In fact, a reduction in revascularization procedures
contributed most to the statistically significant result in
SHARP.4 Even though total mortality was reduced in the 4S
trial (relative risk, 0.70 [95% CI, 0.58-0.85]; P < .001), this
was not the case in SHARP (rate ratio, 1.02 [95% CI, 0.94-
1.11]; P = .63).
Despite the qualitative differences in the benefit demon-
strated in these 2 clinical settings, Ridker and Wilson1 en-
dorsed statin therapy equally for patients with chronic kid-
ney disease as for patients with a history of coronary heart
disease. The authors suggested incorporation of the number
needed to treat metric into clinical decision making, but the
number needed to treat for which outcome?
Guidelines that use oversimplified and ambiguous refer-
ences tobenefit or lackof benefit (without specificationof the
efficacymeasures tested in the relevant trials) are unlikely to
beusable by clinicians andpatients. In our view, before guide-
line panels engage in interpretation and application of evi-
dence, they should first specify for guideline users a hierar-
chy of outcomes that is specific and transparent.5
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To the Editor The Viewpoint on formulation of statin guide-
lines byDrs Ridker andWilson1mayhave unintentionally im-
plied to the clinical community that it is acceptable to focus
on selected evidence over the totality of the evidence. Ridker
andWilson’s exampleof trial-based recommendations for pri-
mary cardiovascular disease prevention includes subgroups
identified through only 6 trials; however, a recent Cochrane
Collaborationsystematic review2ontheeffectof statins forpri-
mary cardiovascular disease prevention identified 18 trials.
In concert with recommendations from the Institute of
Medicine, we favor using systematic reviews of the evidence
over evidence fromindividual trials todrawconclusionsabout
theeffectivenessof an intervention.3 Systematic reviewshave
a transparent, reproduciblemethod that assesses the totality
of evidence on a topic, including the risk of bias in the iden-
tified studies, and synthesizes that information quantita-
tively,whenappropriate, throughmeta-analyses.Whenclini-
cal practice guidelines use systematic reviews to support
recommendations, opportunities for bias are minimized.
Weare encouraged that theUS cholesterol guidelineswill
incorporate systematic reviews,4 even though earlier guide-
lines did not. Similar to the authors, we believe that guide-
lines should be updated frequently to account for accrual of
new data, but we also argue that systematic review updates
provide the appropriate framework to do so.
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In ReplyWeconcurwithDrO’Sullivan andMsBrown that only
those trials that use actual clinical outcomes should inform
practice. For thegreatmajority of trials thatwecited, the com-
monendpointwas inclusive ofmyocardial infarction, stroke,
revascularization for unstable angina, or vascular death.How
one chooses toweight those outcomes is amatter of opinion,
andthuswediffer somewhat fromO’SullivanandBrowninthat
we believe a reduction in the need for angioplasty or bypass
surgery is a relevant benefit for patients.
By contrast, we firmly believe that studies based on sur-
rogate endpoints shouldhave little if any role in guidelinedis-
cussions. We respectfully disagree with Drs Huffman, Ebra-
him, andDickersin that comprehensive is better than relevant
or that meta-analysis automatically trumps individual trial
data. The 6 studies evaluated in our analysis of primary pre-
vention include all trials ever conducted that address the fun-
damental hypotheses of whether or not statin therapy re-
duceshardclinical events inpopulationsknownat thebaseline
evaluation to be free of cardiovascular disease.
We are surprised to learn that the Cochrane meta-
analysis of statins in primary prevention1 included not only
these core relevant studies but also analyzed studies inwhich
the trial’s primaryaimwas toaddress changes in surrogateend
points such as carotid thickness, low-density lipoprotein cho-
lesterol level, blood pressure, and bone density. Our omis-
sion of such trialswas intentional, andwe believewell within
the fundamental spirit of the InstituteofMedicine recommen-
dation to rely on hard evidence and on the simple concept of
“whatworks and inwhom?”2Wenote that other high-quality
meta-analyses such as those routinely performedby theCho-
lesterol Treatment Trialist Collaboration also elect to exclude
surrogate end point studies.
Surrogate end point trials tend to be of small sample size
and add virtually no power to the overall analysis. Thus, the
Cochrane approach comes to a similar conclusion as our ap-
proach, although we believe it puts an unfortunate distance
between the actual trial data and the clinician responsible for
patient care.
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CORRECTION
Incorrect Language: In theOriginal Investigation entitled “Association of Testos-
teroneTherapyWithMortality,Myocardial Infarction, andStroke inMenWithLow
Testosterone Levels” published in the November 6, 2013, issue of JAMA (2012;
310[17]1829-1836.doi:10.1001/jama.2013.280386), incorrect languagewasused.
The fourth sentence of the Results section of the Abstract should read “At 3 years
after coronary angiography, theKaplan-Meier estimated cumulative percentages
with eventswere 19.9% in the no testosterone therapy group vs 25.7% in the tes-
tosterone therapy group,with an absolute risk difference of 5.8% (95%CI, −1.4%
to 13.1%).” The fifth sentence in the thirdparagraphof theResults section, the sen-
tenceshouldread“TheKaplan-Meierestimatedcumulativepercentageswithevents
among theno testosterone therapygroupvs testosterone therapygroupat 1 year
after coronary angiography were 10.1% vs 11.3%; at 2 years, 15.4% vs 18.5%; and
at 3 years, 19.9% vs 25.7.” This article has been corrected online.
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